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Figure legends 
 
Table S1. Complete candidate list 
For each clone the fold-change of reporter activity is shown. For each individual 
gene, expression patterns were determined at all three stages of the wave 
spread using standard WISH. Wherever was possible, ensembl IDs were 
assigned to the clones, otherwise we assigned identifiers corresponding to the 
medaka genome project. 
 
Table S2. Dose response experiments 
(A) Dose-response data using CMV promoter-driven control reporter (B) 
Dose-response data using SV40 promoter-driven control reporter For each 
clone four different concentrations of candidate regulator were transfected. 
Candidates showing a linear dose-response are indicated in both. 
 
Figure S1. Behavior of known regulators under screening conditions  
Known regulators of Ath5 were added at increasing concentration to the reporter 
assay. X-axis denotes the amount of regulator added per well. The y-axis shows 
fold-changes of luminescence normalized against an empty vector control. Ath5 
and Pax6 effect as activators, and Hes-1 repressive activity are consistent with 
previously published results. 
 
Figure S2. Automatized in situ hybridization screen. 
Representative examples of expression patterns obtained in in situ hybridization 
screen. Expression was determined at three stages, initiation stage (stg24), 
progression stage (stg27) and steady wave stage (stg31). Relevant stages for 
representative examples are shown as dorsal whole mount images, anterior is to 
the left. A-F Group 1, repressors expressed in RPCs; G-I Group 2, SRP40, an 
activator expressed in RPCs; J,K Group 3, Islet-2, activator expressed in RGCs, 
L, RBPMS2, repressor in RGCs. M: ubiquitously expressed gene, p65; N,O 
genes expressed elsewhere, cytokeratin and MBX-S. 
 
Figure S3. Double-fluorescent whole-mount in situ hybridization of 
candidates (supplementary) 
All images are single horizontal confocal sections of the developing eye at the 
level of the lens with the embryo facing left. Ath5 mRNA was detected using 
TSA-fluorescein (shown in green), regulator mRNA was visualized using 
FastRed staining (shown in purple). 
 
Figure S4 Analysis of 3kb regulatory Ath5 sequence  
(A) conservation and TFBS analysis. Conserved sequences within fish species 
are shown in green. Putative transcription factor bindings sites (TFBS) were 
detected using the respective PWMs.  
(B) Functional test of conserved TFBS. For each of the conserved TFBS 
labeled in red in (A) a 24bp fragment containing the TFBS was cloned upstream 
a luciferase gene coupled to a minimal promoter. The reporters were transfected 
with increasing amounts of the respective regulator under the control of the CMV-
promoter. The relative luminescence normalized against a pCS2+ control is 
represented in the graphs. The numbers in brackets refer to the numbers TFBS 
in (A)  
Supplementary table 2 – dose-response data 
(A)  
Name GO  20ng/ well 40ng/ well 80ng/ well 160ng/ well 
Clones with a linear dose-response     
ARG1  1.45 ± 0.06 0.48 ± 0.03 0.61 ± 0.03 0.61 ± 0.01 
Bcat2 Nucleic acid binding 0.97 ± 0.05 1.11 ± 0.02 1.88 ± 0.21 1.77 ± 0.12 
cbx7 Nucleic acid binding 0.37 ± 0.05 1.97 ± 0.12 2.88 ± 0.04 4.18 ± 0.14 
CEB55  0.84 ± 0.11 1.06 ± 0.09 1.08 ± 0.04 1.62 ± 0.32 
Cnot10 Other transcription factor 0.48 ± 0.07 0.50 ± 0.02 0.53 ± 0.03 0.71 ± 0.02 
ELG protein  0.47 ± 0.07 1.06 ± 0.03 2.12 ± 0.51 1.98 ± 0.15 
FAN  0.66 ± 0.02 0.99 ± 0.05 1.02 ± 0.03 1.27 ± 0.07 
GPI deacylase Nucleic acid binding 0.99 ± 0.09 1.24 ± 0.04 1.55 ± 0.08 2.42 ± 0.29 
Idax  0.33 ± 0.04 0.34 ± 0.00 0.32 ± 0.02 0.23 ± 0.03 
Islet2 Transcription factor 1.45 ± 0.10 2.27 ± 0.32 3.76 ± 0.17 7.27 ± 2.01 
KPNA4 Other transcription factor 0.64 ± 0.04 0.80 ± 0.04 0.66 ± 0.03 0.58 ± 0.02 
MCM3 Nucleic acid binding 0.68 ± 0.05 0.69 ± 0.07 0.64 ± 0.01 0.56 ± 0.03 
Ndrg3a  0.50 ± 0.03 0.61 ± 0.07 0.74 ± 0.02 1.31 ± 0.32 
NHL-protein  0.74 ± 0.16 0.47 ± 0.03 0.38 ± 0.02 0.48 ± 0.04 
p65 TF Transcription factor 0.57 ± 0.03 1.43 ± 0.07 2.13 ± 0.03 5.15 ± 1.07 
PTPN2  1.06 ± 0.06 0.93 ± 0.07 1.29 ± 0.07 1.45 ± 0.01 
Rb1 Other transcription factor 1.09 ± 0.08 1.04 ± 0.10 1.44 ± 0.07 1.71 ± 0.01 
RBPMS2 Nucleic acid binding 0.61 ± 0.03 0.60 ± 0.04 0.63 ± 0.06 0.75 ± 0.05 
sFRP-1  0.59 ± 0.03 0.79 ± 0.06 0.41 ± 0.08 0.39 ± 0.09 
SRP40 Nucleic acid binding 0.76 ± 0.08 1.82 ± 0.11 2.28 ± 0.19 3.11 ± 0.27 
Sterol demethylase  1.47 ± 0.08 1.40 ± 0.15 1.86 ± 0.07 2.56 ± 0.21 
Thiolase  0.87 ± 0.10 0.97 ± 0.04 1.21 ± 0.18 2.06 ± 0.27 
Transferase  1.05 ± 0.05 1.12 ± 0.11 1.36 ± 0.05 1.50 ± 0.06 
USP25  0.59 ± 0.06 0.64 ± 0.10 0.72 ± 0.04 0.62 ± 0.07 
Zfp 161  0.61 ± 0.02 0.40 ± 0.02 0.34 ± 0.02 0.28 ± 0.02 
Clones without a linear dose-response     
ATP-Synthase  1.08 ± 0.05 0.72 ± 0.07 0.72 ± 0.05 8.58 ± 1.83 
bub3  0.62 ± 0.02 0.74 ± 0.02 0.71 ± 0.03 1.01 ± 0.28 
DuS4L  0.80 ± 0.05 1.01 ± 0.12 1.31 ± 0.06 1.95 ± 0.13 
EF-1-alpha  1.03 ± 0.18 0.84 ± 0.05 1.15 ± 0.07 1.55 ± 0.14 
Hsp1  0.74 ± 0.13 0.99 ± 0.09 1.02 ± 0.06 1.33 ± 0.22 
KPNA2 Other transcription factor 1.08 ± 0.03 0.93 ± 0.06 1.12 ± 0.02 1.38 ± 0.04 
MCM2 Other transcription factor 0.84 ± 0.04 1.12 ± 0.04 1.47 ± 0.03 1.58 ± 0.03 
MRPL47 Nucleic acid binding 0.67 ± 0.05 0.83 ± 0.07 0.73 ± 0.07 0.85 ± 0.06 
NHL-protein II  0.85 ± 0.04 0.75 ± 0.04 1.00 ± 0.05 1.09 ± 0.08 
RBM4L  0.56 ± 0.02 0.51 ± 0.02 0.70 ± 0.15 0.60 ± 0.03 
Ribonuclease Other transcription factor 0.80 ± 0.05 0.84 ± 0.04 0.89 ± 0.06 1.21 ± 0.21 
Samd11  0.79 ± 0.16 0.83 ± 0.07 0.86 ± 0.06 1.47 ± 0.23 
TARBP2 Nucleic acid binding 0.61 ± 0.06 0.74 ± 0.06 0.58 ± 0.03 0.84 ± 0.06 
Tetraspanin-9 Other transcription factor 0.76 ± 0.06 0.73 ± 0.01 0.93 ± 0.01 1.17 ± 0.04 
TMEM79  0.64 ± 0.04 1.06 ± 0.08 1.09 ± 0.07 1.54 ± 0.06 
tubulin-like  0.60 ± 0.07 0.71 ± 0.03 0.95 ± 0.02 0.89 ± 0.03 
UBR2  0.80 ± 0.19 1.04 ± 0.04 1.03 ± 0.03 0.00 ± 0.00 
Uncharacterized 3  1.28 ± 0.09 0.73 ± 0.03 1.01 ± 0.06 1.33 ± 0.16 
USP1 Nucleic acid binding 0.57 ± 0.02 0.97 ± 0.03 0.67 ± 0.02 0.81 ± 0.03 
WDR43  0.67 ± 0.11 1.43 ± 0.19 1.39 ± 0.09 1.23 ± 0.05 
 
(B) 
Name 20ng/ well 40ng/ well 80ng/ well 160ng/ well 
Clones with a linear dose-response    
Bcat2 0.91 ± 0.07 1.04 ± 0.10 1.35 ± 0.15 1.59 ± 0.20 
Cbx7 1.25 ± 0.06 1.54 ± 0.16 1.83 ± 0.14 2.96 ± 0.06 
CEB55 1.23 ± 0.14 1.07 ± 0.36 1.51 ± 0.54 2.69 ± 0.17 
Cnot10 0.42 ± 0.11 0.51 ± 0.07 0.43 ± 0.03 0.44 ± 0.04 
DuS4L 0.51 ± 0.04 0.52 ± 0.06 0.48 ± 0.02 0.58 ± 0.01 
ELG protein 0.42 ± 0.05 0.49 ± 0.04 0.43 ± 0.07 0.56 ± 0.04 
GPI deacylase 1.01 ± 0.08 1.29 ± 0.06 1.75 ± 0.39 2.18 ± 0.08 
Idax 0.19 ± 0.01 0.20 ± 0.02 0.16 ± 0.01 0.17 ± 0.03 
Islet2 0.95 ± 0.06 1.76 ± 0.14 2.06 ± 0.06 4.36 ± 0.41 
KPNA4 0.43 ± 0.01 0.42 ± 0.03 0.38 ± 0.01 0.44± 0.04 
MCM2 0.55 ± 0.06 0.62 ± 0.03 0.62 ± 0.08 0.71 ± 0.07 
MCM3 0.58 ± 0.03 0.537 ± 0.018 0.445 ± 0.013 0.425 ± 0.047 
Ndrg3a 0.99 ± 0.15 0.63 ± 0.02 0.70 ± 0.03 0.70 ± 0.04 
NHL-protein 0.55 ± 0.03 0.59 ± 0.02 0.57 ± 0.06 0.62 ± 0.09 
p65 TF 1.73 ± 0.29 7.67 ± 1.24 15.66 ± 0.62 29.58 ± 2.94 
PTPN2 1.45 ± 0.42 0.90 ± 0.33 0.76 ± 0.20 0.63 ± 0.07 
Rb1 2.09 ± 0.24 1.87 ± 0.41 1.38 ± 0.09 1.18 ± 0.14 
RBPMS2 0.62 ± 0.07 0.55 ± 0.05 0.84 ± 0.24 7.81 ± 1.23 
Samd11 0.81 ± 0.22 0.60 ± 0.06 0.57 ± 0.05 0.53 ± 0.03 
sFRP-1 1.92 ± 0.13 2.75 ± 0.19 4.78 ± 0.64 6.04 ± 0.84 
SRP40 0.93 ± 0.01 1.00 ± 0.08 1.13 ± 0.12 1.37 ± 0.07 
Sterol demethylase 0.91 ± 0.05 1.55 ± 0.12 1.47 ± 0.03 2.60 ± 0.10 
TARBP2 0.52 ± 0.03 0.31 ± 0.02 0.36 ± 0.07 0.32 ± 0.04 
Tetraspanin-9 0.81 ± 0.04 0.99 ± 0.15 1.01 ± 0.08 2.15 ± 0.25 
Thiolase 0.91 ± 0.11 1.23 ± 0.09 1.86 ± 0.08 3.33 ± 0.21 
TMP49 0.55 ± 0.01 0.59 ± 0.03 0.70 ± 0.00 1.18 ± 0.08 
USP1 0.71 ± 0.06 0.73 ± 0.16 0.38 ± 0.09 0.48 ± 0.04 
Zfp 161 0.68 ± 0.04 0.63 ± 0.01 0.65 ± 0.04 0.64 ± 0.02 
Clones without a linear dose-response    
ARG1 0.68 ± 0.10 1.11 ± 0.52 0.90 ± 0.27 0.92 ± 0.16 
Bub3 0.84 ± 0.25 1.05 ± 0.29 0.79 ± 0.06 1.09 ± 0.08 
KPNA2 0.88 ± 0.13 1.14 ± 0.27 0.92 ± 0.12 1.12 ± 0.12 
MRPL47 0.72 ± 0.11 0.77 ± 0.03 0.62 ± 0.12 1.38 ± 0.20 
Ribonuclease 0.75 ± 0.09 0.62 ± 0.03 0.76 ± 0.11 0.73 ± 0.05 
Uncharacterized 3 0.77 ± 0.29 0.97 ± 0.13 0.77 ± 0.14 0.74 ± 0.16 
USP25 0.85 ± 0.13 1.10 ± 0.27 0.72 ± 0.22 0.75 ± 0.06 
WDR43 0.70 ± 0.05 1.17 ± 0.26 0.80 ± 0.19 0.824± 0.15 
 
Table S1 - List of candidates 
 
Repressors    
Name Fold-change expressed  ID 
CRTAP 0.16 ± 0.01 Elsewhere ENSORLG00000011852 
Idax 0.16 ± 0.01 In RGCs ENSORLG00000006474 
Cnot10 0.17 ± 0.02 In RPCs ENSORLG00000003576 
LPP3-like 0.18 ± 0.00 Elsewhere ENSORLG00000006759 
TOR1AIP1 0.19 ± 0.00 No expression ENSORLG00000016657 
RBPMS2 0.20 ± 0.06 In RGCs ENSORLG00000001493 
AATF 0.21 ± 0.02 In RPCs ENSORLG00000013628 
Uncharacterized 1 0.22 ± 0.01 Ubiquitous UTOLAPRE05100106330 
RBM4L 0.23 ± 0.01 In RGCs ENSORLG00000011589 
Zfp 410 0.24 ± 0.03 Elsewhere ENSORLG00000009376 
Zfp 161 0.24 ± 0.02 In RGCs ENSORLG00000004128 
KPNA4 0.25 ± 0.04 In RPCs ENSORLG00000006226 
Ikaros 0.25 ± 0.03 Elsewhere ENSORLG00000020562 
NHL-protein 0.27 ± 0.00 In RGCs ENSORLG00000014595 
MCM2 0.27 ± 0.00 In RPCs ENSORLG00000003191 
Beta-actin 0.27 ± 0.03 Ubiquitously ENSORLG00000013676 
ARG1 0.27 ± 0.02 In RPCs UTOLAPRE05100101036 
ELG protein 0.27 ± 0.00 In RGCs ENSORLG00000013703 
Tubulin-like 0.27 ± 0.04 Elsewhere ENSORLG00000016464 
Fibronectin-like 0.27 ± 0.03 No expression ENSORLG00000002976 
Actin-like 0.27 ± 0.02 Elsewhere ENSORLG00000017368 
Apo-AI 0.28 ± 0.03 Elsewhere ENSORLG00000015744  
DuS4L 0.28 ± 0.01 In RPCs ENSORLG00000008306 
USP25 0.28 ± 0.05 In RPCs ENSORLG00000000577 
MBX-S 0.28 ± 0.01 Elsewhere ENSORLG00000008964 
Hsbp1 0.28 ± 0.02 Elsewhere ENSORLG00000015789 
ATP-Synthase 0.28 ± 0.04 In RPCs ENSORLG00000003517 
WDR43 0.29 ± 0.04 In RPCs ENSORLG00000018236 
Activators    
Name Fold-change expressed ID 
SRP40 2.88 ± 0.10 In RPCs ENSORLG00000009268 
Heatr5B 2.91 ± 0.31 No expression ENSORLG00000012398 
HMG 2.93 ± 0.49 Ubiquitously ENSORLG00000008779 
Bcat2 2.93 ± 0.27 In RPCs ENSORLG00000001573 
Cbx7 2.96 ± 0.14 In RPCs ENSORLG00000013869 
sFRP-1 2.97 ± 0.55 In RPCs ENSORLG00000016179 
Nfkbia 2.99 ± 0.44 Ubiquitously ENSORLG00000017687 
Tetraspanin 31 3.00 ± 0.38 In RGCs ENSORLG00000016592 
MCM3 3.00 ± 0.00 In RPCs ENSORLG00000016187 
FBXL3 3.00 ± 0.48 No expression ENSORLG00000011408 
TMEM79 3.01 ± 0.30 In RPCs ENSORLG00000008212 
TARBP2 3.05 ± 0.18 In RPCs ENSORLG00000005209 
GNS 3.12 ± 0.27 Elsewhere ENSORLG00000016835 
PFKFB4 3.12 ± 0.36 No expression ENSORLG00000013355 
UBR2 3.18 ± 0.36 Ubiquitously ENSORLG00000003350 
MNAT1 3.22 ± 0.00 No expression ENSORLG00000015749 
USP1 3.24 ± 0.34 In RPCs ENSORLG00000010503 
Coiled-coil 
contain. 
3.25 ± 0.43 Ubiquitously 
UTOLAPRE05100105142 
PYGL 3.27 ± 0.50 elsewhere ENSORLG00000008955 
Tubulin beta-chain 3.28 ± 0.59 ubiquitously ENSORLG00000016464 
FAN 3.28 ± 0.28 in RPCs ENSORLG00000005939 
Tetraspanin-9 3.29 ± 0.00 in RPCs ENSORLG00000016594 
EF-1-alpha 3.31 ± 0.26 Ubiquitously ENSORLG00000007614 
Ankrd43 3.33 ± 0.41 No expression ENSORLG00000005833 
MRPL47 3.33 ± 0.00 In RPCs ENSORLG00000005717 
Sterol 
demethylase 
3.33 ± 0.33 In RPCs ENSORLG00000020002 
Cytokeratin-8 3.33 ± 0.22 Elsewhere UTOLAPRE05100109764 
NHL-domain II 3.36 ± 0.59 In RPCs ENSORLG00000014595 
Transferase 3.39 ± 0.58 In RPCs ENSORLG00000015041 
Rb1 3.50 ± 0.45 In RPCs ENSORLG00000008317 
Aldh1a2 3.53 ± 0.00 Elsewhere ENSORLG00000008319 
OTCase 3.55 ± 0.00 Elsewhere ENSORLG00000009056 
PTPN2 3.65 ± 0.59 In RPCs ENSORLG00000002826 
KPNA2 3.65 ± 0.36 In RPCs ENSORLG00000015192, 
Synthropin 3.69 ± 0.16 No expression UTOLAPRE05100112103 
Ndrg3a 3.73 ± 0.00 In RGCs ENSORLG00000013821 
Sox-14 3.74 ± 0.33 Elsewhere ENSORLG00000011685 
MRTF-8 3.75 ± 0.44 No expression ENSORLG00000005094 
Jun 3.76 ± 0.24 No expression ENSORLG00000017506 
Nfkbie 3.80 ± 0.15 No expression ENSORLG00000009824 
FBXW5 3.86 ± 0.36 Elsewhere ENSORLG00000007130 
PPAP2C 3.86 ± 0.00 Elsewhere ENSORLG00000014235 
ERG 3.89 ± 0.12 Elsewhere ENSORLG00000015940 
TMP49 3.92 ± 0.42 No expression ENSORLG00000012702 
ARNT2 4.08 ± 0.78 Elsewhere ENSORLG00000019479 
Grou2 rTLE3 4.12 ± 0.09 Elsewhere ENSORLG00000006700 
Ribonuclease 4.15 ± 0.09 In RPCs ENSORLG00000004042 
Sfrs4 4.23 ± 0.23 No expression ENSORLG00000009430 
Aminoacylase-1 4.24 ± 0.00 No expression ENSORLG00000002219 
Rab-18 4.63 ± 0.00 Elsewhere ENSORLG00000009609 
CEB55 4.70 ± 0.39 In RPCs ENSORLG00000005053 
Bub3 4.85 ± 0.00 In RPCs ENSORLG00000018829 
Thiolase 4.98 ± 0.32 In RPCs ENSORLG00000009609 
Islet2 5.11 ± 0.22 In RGCs ENSORLG00000012362 
WDR45L 5.16 ± 0.77 No expression ENSORLG00000012984 
CRMp4 5.28 ± 0.61 Elsewhere ENSORLG00000019028 
Ankrd39 5.40 ± 0.71 Ubiquitously ENSORLG00000014221 
Samd11 5.50 ± 0.00 Elsewhere ENSORLG00000005568 
HoxA9  5.57 ± 0.29 Elsewhere ENSORLG00000005025 
Uncharacterized 2 5.90 ± 0.00 Elsewhere ENSORLG00000001089 
p65 TF 6.16 ± 0.81 Ubiquitously ENSORLG00000011104 
Uncharacterized 3 6.62 ± 0.62 No expression ENSORLG00000017609 
Hsp1 11.02 ± 1.36 In RPCs ENSORLG00000020428 
GPI deacylase 15.00 ± 0.81 In RPCs ENSORLG00000018243 
Deiodinase 16.77 ± 0.20 No expression ENSORLG00000014548 
 




Supplementary methods 
Screening setup 
For each clone the trans-regulatory effect on the Ath5 promoter was tested in 
triplicate. The cDNAs were supplied as DNA mini-preparations in TE-buffer in 96-well 
plates by the in-house EMBL genomic service. For each round of seeding, 
transfection and luciferase assays 8 96-well plates of clones were assayed in 
triplicate, i.e. 24 96-well plates of cells were handled per round of screening. From 
each well 6µl containing an average of 300ng of DNA were transferred into a fresh 
96-well plate using a 12-channel pipette. In parallel pGL3 Ath5::Luc and pRL-CMV 
were added to serum-free medium and mixed well. Transfection reagent was added 
and mixed with the DNA solution. Using an 8-channel multistep pipette 150µl of the 
solution were immediately added to the cDNA solution in the 96-well plates and 
incubated for 30min. 48µl of this DNA-transfection reagent mixture were then added 
to the cell as described below.  
Component Amount/ volume per well 
pGL3 Ath5::Luc 40ng 
pRL-CMV 5ng 
pCMV-Sport6.1::cDNA 2µl (on average 80ng) 
FuGENE6 transfection reagent 435nl 
Table 1 Transfected components per well in large scale screen 
 
Transfection and passive lysis 
Prior to transfection, cells of a 9cm Petri dish at 90% confluency were trypsinised, 
detached from each other by pipetting up and down and resuspended in 10ml of 
standard medium. This stock suspension was diluted 1:30 in fresh standard medium. 
200µl of this working suspension were transferred into each well of a white-bottom 
96-well plate1 using a multichannel-multistep pipette2. Cells were then allowed to re-
attach to the bottom of the well and grow for 5h-6h until they reached 50% 
confluency. Prior to transfection the different plasmids were mixed with FuGENE6 
transfection reagent3 in serum-free medium4 at room temperature. For each well 
40ng of pGL3 Ath5::luc2 vector, 5ng of pRL-CMV vector and 10ng-300ng of pCMV-
Sport6.1::cDNA were mixed with 3-6fold volume-excess of FuGENE6 transfection 
reagent in 50µl serum-free medium. After a 30min incubation the mixture was added 
drop-wise into the 96-well plates containing the cells. Cells were allowed to grow for 
42h at 37°C. The medium was removed and cells were lysed with 1X passive lysis 
buffer5 for 15min while shaking. To avoid loss of luciferase activity the lysate was 
immediately used for luminescence assays. Alternatively, plates were kept at 4°C for 
up to 6 hours.  
Luciferase assays 
Luciferase assays were carried out in a luminometer6 containing two dispensers and 
a stacker device. Substrates for the assays were obtained from a commercial 
supplier7. The LARII solution was prepared in advance and frozen in aliquots at -
80°C. The Stop&Glow solution was prepared freshly for each luminometer run. 
Leftovers were frozen for one month maximum at -80°C and mixed with fresh 
Stop&Glow solution. Measurements were carried out for one well after the other. 
After addition of 45µl LARII reagent containing the substrate luciferin for the firefly 
                                                
1 OptiPlate-96, White Opaque 96-well Microplate, PerkinElmer, Rodgau-Jügesheim, Germany, Cat.-No. 
6005299 
2 ResearchPro, 50-1.200 µl, 8-channel, Eppendorf, Hamburg, Germany, Cat.-No. 4860 000.577 
3 FuGENE6 Transfection Reagent, Roche Diagnostics GmbH, Mannheim, Germany, Cat.-No. 11988387001 
4 Opti-MEM® I Reduced Serum Medium (1X), liquid - with L-Glutamine, Invitrogen, Karlsruhe, Germany, 
Cat.-No. 31985-047 
5 Passive Lysis 5X Buffer, Promega, Mannheim, Germany, Cat.-No. E1941 
6 VICTOR Light Luminescence Counter, PerkinElmer, Rodgau-Jügesheim, Germany, Cat.-No. 1420-060 
7 Dual-Luciferase® Reporter 1000 Assay System, Promega, Mannheim, Germany, Cat.-No. E1980 
luciferase a delay of 1.6 seconds before starting the measurement allowed complete 
mixing of the reagent with the lysate. The intensity of the luminescence was recorded 
for 4 seconds. Subsequently 45µl of Stop&Glow solution were added through the 
second dispenser, quenching the luminescence of the firefly luciferase and supplying 
the substrate for the Renilla luciferase, coelenterazine. After another delay of 1.6 
seconds the luminescence of the control luciferase was recorded for 2 seconds. See 
complete program in supplementary methods.  
Dose-response assays 
Amount of candidate cDNA Amount of pCS2+ 
12.5ng 87.5ng 
25ng 75ng 
50ng 50ng 
100ng 0ng 
Table 2 Dose-response candidate cDNA amount per well 
Dual-luciferase assay program for Victor Light luminometer 
 Description Specifications Values 
Injector 1 
Speed 5 
Volume  45 µL 
Increment 0 µL 
Replicate 1 
Injection mode aspVol=dispVol 
1 Injection of LARII 
solution 
Repeated operation Yes 
Shaking duration 1.6 s 
Shaking speed Fast 
Shaking diameter 0.20 mm 
Shaking type Linear 
2 Mixing of LARII and 
lysate 
Repeated operation Yes 
Name of the label CPS-1s 
Label technology Luminometry 
Emission filter name No filter 
Emission filter slot A7 
Measurement time 1.0 s 
3 Measurement of 
firefly luciferase 
signal 
Emission aperture Normal 
Name of the label CPS-1s 
Label technology Luminometry 
Emission filter name No filter 
Emission filter slot A7 
Measurement time 1.0 s 
4 Measurement of 
firefly luciferase 
signal 
Emission aperture Normal 
Name of the label CPS-1s 
Label technology Luminometry 
Emission filter name No filter 
Emission filter slot A7 
Measurement time 1.0 s 
5 Measurement of 
firefly luciferase 
signal 
Emission aperture Normal 
Name of the label CPS-1s 
Label technology Luminometry 
Emission filter name No filter 
Emission filter slot A7 
Measurement time  1.0 s 
6 Measurement of 
firefly luciferase 
signal 
Emission aperture  Normal 
Name of the label  CPS-1s 
Label technology  Luminometry 
Emission filter name  No filter 
Emission filter slot  A7 
Measurement time  1.0 s 
7 Measurement of 
firefly luciferase 
signal 
Emission aperture  Normal 
Injector 2 
Speed 5 
Volume 45 µL 
Increment 0 µL 
Replicate 1 
Injection mode aspVol=dispVol 
8 Injection of 
Stop&Glow solution 
Repeated operation  Yes 
Shaking duration  1.6 s 
Shaking speed  Fast 
Shaking diameter  0.20 mm 
Shaking type  Linear 
9 Mixing of Stop& 
Glow and lysate 
Repeated operation Yes 
 Description Specifications Values 
Name of the label  CPS-1s 
Label technology  Luminometry 
Emission filter name  No filter 
Emission filter slot  A7 
Measurement time  1.0 s 
10 Measurement of 
Renilla luciferase 
signal 
Emission aperture  Normal 
Table 3 VictorLight luminometer program 
 
Data processing 
The raw luminescence data was exported from the VictorLight software as Excel-
sheets, parsed using a custom-tailored parser written in BASIC and imported into the 
database. The raw luminescence values were filtered out if they were below an 
absolute level of 8000 relative units for the Renilla luciferase signal and 100 relative 
units for the firefly signal. The limit for the firefly luciferase signal was 5 times the 
background signal. One value pair of reporter and control signal was only processed 
further if both values were above their respective thresholds.  
Reporter luciferase signals were corrected against the control luciferase signal within 
one value pair. To reduce the effect of outliers within the group of triplicates the 
median was calculated as opposed to the average, see equation 1. The standard 
deviation was calculated according to equation 2. This value was then normalized 
against the average of ratios within this 96-well plate of clones to correct for variation 
between different plates, see equation 3. Standard deviations were normalized with 
the same value. 
The normalized ratios of clones were transformed to log space to allow generating 
symmetry between repressors and activators. A histogram with a bin size of 0.02 and 
a range of -1.00 to +2.00 was calculated using the Prism software8. A Gaussian 
normal distribution was fitted to the data (equation 4). The R2 for the fit was 0.9940, 
indicating the validity of the mathematical approach as the regression curve fits the 
data well. However, the runs test shows a significant deviation from the model in the 
data (p<0.0001 in 31 runs) reflecting the fact that a significant number of clones show 
a more-than-random deviation from the average luminescence ratio. Measured ratios 
below the first or above the second intersection with the x-axis were considered as 
                                                
8 Prism4 for Macintosh, Version 4.0a, GraphPad Software, Inc., San Diego, USA 
high-confidence candidates as they are unlikely to be random variations from the 
mean value, see equation 5(1). 
To determine the standard variation of the ratios, the median of all standard deviation 
was calculated using Prism. Ratios with relative standard deviations larger than the 
median of all ratios plus the standard deviation of the median were excluded from 
this high-confidence candidate list; see equation 5(2). 
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Equation 2 Calculation of standard deviation 
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Equation 3 corrected of median ratio across plate 
 
 
! 
y =
A
" 2#
e
$
(
x$x 
"
)
2
2 , A= integral area of graph, σ = standard deviation of data, y= value on y-axis for 
any x, 
! 
x =mean of x-values  
Equation 4 Gaussian distribution for ratios 
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(1)ratio(i)corrected < thresholdrepressor " ratio(i)corrected > thresholdactivator   ,threshold= global 
thresholds 
! 
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˜ "  =median of all standard deviations, σ(σ)= 
standard deviation of all standard deviations 
Equation 5 Criteria for high-confidence candidates 
 In situ hybridization robot Intavis InSituPro program specification 
 Command Parameters Comment 
1 SetTempReg       T0 (OFF)  
2 PrimeNeedle      12000  
3 IncubateVT       15 min 150 PTW->Specimen Wash with PTw 
4 IncubateVT       15 min 150 Hyb-mix->Specimen Wash Hyb.-Mix 
5 SetTempReg       T2 (HIGH)  
6 IncubateVT       1 h 150 Hyb-mix->Specimen Prehybridization 
7 IncubateVT       8 h 200 Probe->Specimen Hybridization 
8 IncubateVT       8 min 200 2xSSC/50%FA->Specimen  5x Posthybwash 1 
9 IncubateVT       10 min 200 2xSSC/50%FA->Specimen Posthybwash 1 
10 IncubateVT       8 min 200 2xSSC->Specimen  5x Posthybwash 2 
11 IncubateVT       10 min 200 2xSSC->Specimen Posthybwash 2 
12 IncubateVT       8 min 200 0.2xSSC->Specimen  5x Posthybwash 3 
13 IncubateVT       10 min 150 0.2xSSC->Specimen Posthybwash 3 
14 SetTempReg       T0 (OFF)  
15 Wait             30 min  
16 IncubateVT       10 min 150 PTW->Specimen  2x PTw 
17 IncubateVT       1 h 200 Blocking soln->Specimen Blocking 
18 IncubateVT       4 h 200 Dig antibody->Specimen DIG antibody 
19 IncubateVT       8 min 200 PTW->Specimen  8x PTw 
20 IncubateVT       8 min 200 Prestaining buffer->Specimen  2x Prestain Buffer 
21 Pause             
Add staining buffer to 
position G and press 
return 
22 IncubateVT       8 min 200 Staining buffer->Specimen  2x Staining buffer 
23 PrimeNeedle      12000  
24 SetTempReg       T0 (OFF)  
Table 4 Intavis InSituPro robot program 
 
Vial  Buffer  Volume ml 
A PTW   72.6 
A2   
B Hyb-mix   10.2 
C 2xSSC/50%FA   37.6 
D 2xSSC   37.6 
E 0.2xSSC   36.1 
F Prestaining buffer   13.2 
G Staining buffer   13.2 
H   
I   
J   
K   
L Blocking solution    7.1 
M Dig antibody    7.1 
Reservoir   224.0 
 Basket  Specimen  Probe 
Table 5 Loading form for InSitu Robot Volumes indicated are for 30 probes. Positions are 
named according to standard nomenclature of manufacturer 
Transregulation screen database description 
 
Figure 1 Database Graphical User Interface (GUI) Four of the five existing main GUI displays 
are depicted here. The user can toggle between the displays using the tab labels at the top of the 
display. The top section of all displays is the identical. From left to right it contains the clone id, the 
name of the gene if available, the fold-change in corrected luminescence ration in the screen, the 
number of successful and total number of assays and a candidate id if applicable. (A) Main display. 
The first panel from top to bottom contains a short description and the position of the clone in 96- and 
384-well format. The second panel gives information about the gene linked to the clone. Information 
for both forward and reverse read of the clone is available. The radio buttons give information whether 
the clone has been re-sequenced. The next panel holds a field for comments as well as three buttons 
for extracting candidates, creating expression pattern reports and exporting candidate clone 
information to other programs. The bottommost panel contains administrative information, a link to the 
statistics page and the global thresholds set for defining candidates. (B) The first panel contains the 
raw luminescence values and two links to other representations of the raw data. The second panel 
contains the filtered raw data and the raw ratios. The third panel contains the corrected ratio, the 
absolute corrected standard deviation and standard deviation in relation to the corrected ratio. It also 
contains the average of all standard deviations across the screen and their standard deviation. (C) 
The “In situ” tab contains all information about available expression data. The first panel contains 
manually annotated expression pattern information. The second panel holds a list of pictures with the 
orientation and stage of the embryo depicted. The image list can be scrolled and double-click on a 
picture will open it. The two radio buttons indicate the presence or absence of PCR products and 
riboprobes for in situ hybridization. Finally, it contains the in situ category. The tab “Reference” is not 
shown as it only contains a list of referenced files similar to the “In situ tab” (D) This display contains 
all information about the dose-response curve using CMV::Renilla (second panel) or SV40::Renilla 
(third panel) as a control. Each of the two panels contains a check box that indicates the summary of 
the dose-response experiment. In addition the corrected ratios of the different concentrations of 
regulatory clones together with their standard deviation are shown. The ratio is either normalized 
against a negative control (first column) or against the lowest concentration of regulator (second 
column). The third column shows the raw values. The uppermost panel contains some additional 
practical information about the availability of a retransformed clone. 
Generation of fusion proteins 
Name  Identifiers  Primer sequence 
ENSORLG00000013703 Frw CCGGAATTCAGC ATGGAGGTGGAGGAGGGCGAG ELG 
protein  Rev CTTGCTCACCATGGC 
GGCGTCAAAGTCGTCGCTGCTGT 
ENSORLG00000014595 Frw CCGGAATTCAGC ATGCTGCTGCTGAAGAGGAG NHL 
protein  Rev CTTGCTCACCATGGC 
GACCACGTACGTGCCTAGGCTGAA 
Ndrg3 ENSORLG00000013821 Frw CCGGAATTCAGC ATGTCAACTGTTTTGGACCTGGA 
Name  Identifiers  Primer sequence 
  Rev CTTGCTCATCATGAC 
ACACGAGACCTCCATGGTCTGA 
ENSORLG00000009268 Frw CCGGAATTCAGC  ATGAGTGGAAGTCGCGTCTTCA SRP40 
 Rev CTTGCTCACCATGGC 
GTGTTTGCTGTCTGCCGAGGG 
ENSORLG00000004128 Frw CCGGAATTCAGC ATGTCTGACCTACTGAGATACA Zfp161 
 Rev CTTGCTCATCATGAC 
GCAGTCTCCTGAGTTGTGCGA 
ENSORLG00000001493 Frw CCGGAATTCAGC ATGTATATTAACACGACAGT RBPMS2 
 Rev CTTGCTCACCATGGC 
CTTCAGCTGGACAAAGGTATG 
Table 6 Fusion protein cloning primers 
